Medscape
The addition of nivolumab to rucaparib did not lead to better progression-free survival than rucaparib monotherapy in patients with newly diagnosed, advanced, high-grade ovarian cancer (AHGOC), a new study has found. Bradley J. Monk, MD, presented this finding and other results of the ATHENA-COMBO study, at the European Society for Medical Oncology Congress 2024. …
Read More
Worse PFS Seen with Nivolumab-Rucaparib in Ovarian Cancer
Yuri Schroeder
14:30
The addition of nivolumab to rucaparib did not lead to better progression-free survival than rucaparib monotherapy in patients with newly diagnosed, advanced, high-grade ovarian cancer (AHGOC), a new study has found. Bradley J. Monk, MD, presented this finding and other results of the ATHENA-COMBO study, at the European Society for Medical Oncology Congress 2024. …
